[Triumf-seminars] TRIUMF Special Seminar today at 10:00

TRIUMF Seminars triumf-seminars at lists.triumf.ca
Tue Dec 12 05:00:02 PST 2017


Date/Time: Tue 2017-12-12 at 10:00

Location:  Auditorium          

Speaker:   Sai Kiran Sharma (Memorial Sloan Kettering Cancer Center)

Title:     Insights from the Molecular Imaging of DLL3 - A Low Abundance Therapeutic Target in Small Cell Lung Cancer

Abstract: Delta-like 3 (DLL3) protein, a member of the Notch signaling pathway has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC)1. Rovalpituzumab teserine (Rova-T(tm)) is a first-in-class DLL3-targeted antibody-drug conjugate (ADC) with an encouraging initial safety and efficacy profile in SCLC patients2. This seminar will describe the first molecular imaging of DLL3 and the insights gained from this experience. 

Briefly, the salient features that will be discussed in this presentation include -
A) How tumor expression of DLL3, though orders of magnitude lower than typical oncology targets of immunoPET, can serve as an excellent imaging biomarker to predict response to therapy with the ADC3.
B) How the synthesis of radioimmunoconjugates and the immunobiology of the experimental host can influence the preclinical evaluation of tumor-targeted antibody-based vectors.
C) How DLL3-targeted radioimmunotherapy might add to the arsenal of strategies for the treatment of SCLC. 
Together, this seminar will highlight the strong translational potential of immunoPET as a companion diagnostic in therapeutic trials of ADCs, and advocate for attention to vector design, host immunobiology as well as the need for comprehensive biodistribution studies to be performed early during antibody-based drug development.

References
1.	Saunders, L.R. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 7, 302ra136 (2015).
2.	Rudin, C.M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol 18, 42-51 (2017).
3.	Sharma, S.K. et al. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Res (2017).



______________________________

General TRIUMF seminar information available at http://www.triumf.ca/home/upcoming-events/about-seminars-lectures



More information about the Triumf-seminars mailing list